Log in to your Inderes Free account to see all free content on this page.
Vicore Pharma Holding
10.20 SEK
-0.39 %
Less than 1K followers
VICO
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Vicore Pharma Holding
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 109.4 | 3.8 | |||||
| growth-% | -96.5 % | ||||||
| EBITDA | -92.7 | -146.0 | -291.2 | -287.1 | -255.5 | -184.0 | -452.4 |
| EBIT | -94.0 | -149.5 | -294.8 | -290.7 | -321.5 | -194.2 | -452.4 |
| Profit before taxes | -93.3 | -147.3 | -296.7 | -288.8 | -311.3 | -168.9 | -477.5 |
| Net income | -93.1 | -146.9 | -296.5 | -288.4 | -310.9 | -168.6 | -477.5 |
| EPS | -2.10 | -2.37 | -4.02 | -3.88 | -3.13 | -1.23 | -1.99 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -168.3 % | -11,851.9 % | |||||
| EBIT-% | -177.6 % | -11,851.9 % | |||||
| ROE | -28.9 % | -41.4 % | -77.3 % | -99.8 % | -68.3 % | -14.9 % | -43.6 % |
| ROI | -27.3 % | -36.1 % | -65.7 % | -85.2 % | -62.7 % | -14.0 % | -39.1 % |
Login required
This content is only available for logged in users